DR. JANE SPERRY CHAWLA MD NPI 1487863304

NPI Details

DR. Jane Sperry Chawla, MD is a hematology and oncology internal medicine in Austin, TX with 21 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. DR. Jane Sperry Chawla, MD NPI is 1487863304. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a female.

Education
Medical School: UNIVERSITY OF TEXAS MEDICAL SCHOOL AT SAN ANTONIO
Graduation Year:2005

The provider's business location address is:

6204 BALCONES DR
AUSTIN, TX
ZIP 78731-214
Phone: (512) 427-9400
Fax: (512) 342-7024

The NPI 1487863304 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
• Injection, aprepitant, 1 mg (HCPCS:J0185)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
• Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS:J0881)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml (HCPCS:Q9967)
• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Injection, potassium chloride, per 2 meq (HCPCS:J3480)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Gammaglobulin (immune system protein) measurement (HCPCS:82784)
• Measurement of immunoglobulin light chains (HCPCS:83521)
• Iron level (HCPCS:83540)
• Iron binding capacity (HCPCS:83550)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Ferritin (blood protein) level (HCPCS:82728)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Follow-up hospital inpatient care per day, typically 15 minutes (HCPCS:99231)
• Magnesium level (HCPCS:83735)
• Complete blood cell count (red cells, white blood cell, platelets), automated test (HCPCS:85027)
• Microscopic examination for white blood cells with manual cell count (HCPCS:85007)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a (HCPCS:G9678)
• Immunologic analysis technique on serum (HCPCS:86320)
• Immunologic analysis technique on serum (immunofixation) (HCPCS:86334)
• Unclassified drugs (HCPCS:J3490)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Protein measurement, serum (HCPCS:84165)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Reticulated (young) platelet measurement (HCPCS:85055)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Ct scan of abdomen and pelvis with contrast (HCPCS:74177)
• Ct scan of chest with contrast (HCPCS:71260)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session (HCPCS:G6015)
• Cyanocobalamin (vitamin b-12) level (HCPCS:82607)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Red blood count automated, with additional calculations (HCPCS:85046)
• Application of on-body injector for under skin injection (HCPCS:96377)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Folic acid level, serum (HCPCS:82746)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Administration of influenza virus vaccine (HCPCS:G0008)
• Initial hospital inpatient care per day, typically 50 minutes (HCPCS:99222)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage (HCPCS:90694)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Blood test, basic group of blood chemicals (calcium, total) (HCPCS:80048)
• Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries (HCPCS:A9552)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Nuclear medicine study from skull base to mid-thigh with ct scan (HCPCS:78815)
• Radiation treatment delivery,3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 6-10 mev (HCPCS:G6012)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)

The enumeration date for this NPI number is 5/21/2007 and was last updated on 9/17/2024.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.